JD First Page

Total Page:16

File Type:pdf, Size:1020Kb

JD First Page TRANSFORMATIVE REACTIONS ON CARBOCYCLIC COMPOUNDS A Thesis submitted to the University of North Bengal For the Award of Doctor of Philosophy (Ph.D.) in Chemistry By Jayanta Das Research Guide Prof. Pranab Ghosh DEPARTMENT OF CHEMISTRY UNIVERSITY OF NORTH BENGAL December, 2015 To my parents... i DECLARATION I hereby declare that the thesis entitled “ TRANSFORMATIVE REACTIONS ON CARBOCYCLIC COMPOUNDS ” has been prepared by myself under the guidance of Prof. Pranab Ghosh, Department of Chemistry, University of North Bengal, Drjeeling- 734013. No part of this thesis has formed the basis for the award of any degree or fellowship previously. Jayanta Das Department of Chemistry University of North Bengal Darjeeling – 734 013, India Date: 15.12.2015 ii UNIVERSITY OF NORTH BENGAL Prof. P. Ghosh , Ph: +91 3532776 381 (off) DEPARTMENT OF CHEMISTRY +91 9474441468 (M) University of North Bengal, Fax: +91 353 2699 001 Darjeeling – 734 013, India. Email: [email protected] Date: December 15 , 2015 CERTIFICATE This is to certify that Sri Jayanta Das has prepared the thesis entitled “TRANSFORMATIVE REACTIONS ON CARBOCYCLIC COMPOUNDS ”, for the award of PhD degree of the University of North Bengal, under my guidance. He has carried out the work at the Department of Chemistry, University of North Bengal, Darjeeling, West Bengal-734013. Professor Pranab Ghosh (Research Supervisor) Department of Chemistry University of North Bengal iii Abstract The thesis entitled “Transformative reactions on carbocyclic compounds” comprises four chapters and a brief of their contents are as follows: Chapter I: Carbocyclic compounds and their transformative reactions: A general perspective on natural products chemistry Natural products include any substance produced by life. Now, due to the large extent of catenation capability of carbon, it can produce a large number of molecules made solely by them which in turn, implies that nature provides a huge number of carbocyclic compounds. And in virtue, nature itself is the richest source of a variety of carbocyclic compounds. Two or more carbocycles can be joined together in a number of different fashions to produce a number of different groups of carbocyclic compounds. And among the broad spectrum of all kinds of natural products, if we look for more abundant, easily available and highly useful carbocyclic natural products, we found mainly the steroids and terpenoids. Thus, having the opportunity of working in the field of natural products chemistry, the various known / new transformative reactions were carried out on some selective major steroids (cholesterol, b- sitosterol, ergosterol, diosgenin) and comparatively less-explored but highly potential pentacyclic triterpenoid- friedelin. iv As a consequence, to have a general and very brief overview on the transformative reactions on these substrates, the present chapter demonstrates the important findings revealed so far. Chapter II: First report of solvent selective steroidal aromatization, efficient access to 4b,7 a-dihydroxy steroids, and syntheses of natural diaromatic ergosterols This chapter elaborates the syntheses of natural diaromatic ergosterol derivatives and other steroidal analogues in an unprecedented simple, one-pot and convenient synthetic route. In the process, the key factor- the selectivity of the solvents (having 1,4-ethereal oxygens) towards aromatization has been established. Of note, only ethereal solvents with two oxygens such as 1,4-dioxane, 1,3-dioxalane, 1,2-dimethoxy ethane and 1,2-diethoxy ethane were found able to result selective aromatization. Thorough solvent-dependant study of the model reaction reveals valuable product composition which may be exploited, specially, for the synthesis of biologically important steroid molecules. Efficient access to 4 b,7 a-dihydroxy cholesterol is also described. By using the established solvent-selective steroidal methodology, the yield of the natural product, diaromatic ergosterol was optimized at 12%. Analogous chemistry of b-sitosterol and diosgenin is also reported. Furthermore, single crystal X-ray crystallography has resolved the molecular structures, for the first time in their class, of similar diaromatic cholesterol derivative and triacetylated 4 b,7 a-dihydroxy cholesterol derivative. Chapter III: Polyhydroxy and epoxy-polyhydroxy steroids: design, synthesis and study of their preliminary gelation behaviour The present work associated with this chapter demonstrates basically two aspects of some new polyhydroxy steroids - designed synthesis and their preliminary gelation behavior. v Altogether sixteen polyhydroxy steroids (PHS, 12 new) of cholesteryl and b-sitosteryl series were synthesized and characterized. Among them eight (all new) are, in precise, epoxy- polyhydroxy steroids (5,6-epoxy-3b,4 a-dihydroxy- and 5,6-epoxy-3b,4 a,7 a-trihydroxy-), of which the a-diastereomers were utilized further to synthesize novel new tetraols (3 b,4 b,5 a,6 b-tetrahydroxy-) and pentaols (3 b,4 b,5 a,6 b,7a -pentahydroxy steroids). Thus, epoxidation followed by alkaline-opening of the oxirane-ring of appropriate steroidal 5-ene- 3b,4 b-diols and -5-ene-3b,4 b,7 a-triols, to furnish novel steroidal tetrols and pentols respectively consequences, in practical, a three-step synthetic route for the transformation of 3b,4 b,5 a,6 b-tetrahydroxy- and 3 b,4 b,5 a,6 b,7a -pentahydroxy steroids starting directly from their corresponding basic steroids, cholesterol and b-sitosterol. As a new class of polyhydroxy steroids, preliminary gelation behavior of the molecules was evaluated. At 1% or below CGC (critical gelation concentration), five PHS derivatives were found to be gelators of some selective organic solvents. Some selective organogels were characterized through T gel (gel melting temperature) and related physical parameters ( DH etc.), rheological data, and by morphology analysis (electron microscopes). vi Chapter IV: Syntheses of new friedelane triterpenoids: A-ring modifications including 2-homo derivatives Syntheses of a number of A-ring modified friedelane triterpenoids have been accomplished. These also include the 2-homo derivatives for which, as the key step, the transformation of friedelin with Vilsmeyer-Haack reagent was used. 3-Chloro-2-formylfriedel-2-ene, the main product isolated from the reaction was transformed suitably into various derivatives and hence, following two or three simple steps starting from friedelin, it rendered possible to produce a library of C2,C3-, C3,C4-, and C2,C3,C4- functionalized friedelane triterpenoids. Besides, some useful methodologies were thus established during the various transformative attempts. These include a two-step aromatization of friedelin by N-bromosuccinimide, a one- pot dechlorination with simultaneous C-23 activation, and selective 4 a-hydroxylation with simultaneous oxidation of allylic alcohol by selenium dioxide. Again, syntheses of some friedelane derivatives, viz. , 3b-amino-4a-hydroxy-, 2-carboxamide, 2,3-seco diol, 4a- hydroxy-3-chloro-2-formylfriedel-2-ene and 3-chloro-4a-hydroxy-2-hydroxymethylfriedel- 2-ene, in a few steps, were found very much effective to enrich the A-ring modifications of friedelane triterpenoids. On the other hand, heterocycle-linked (to C3 of friedelanes) 2- homofriedelane derivatives were achieved. We believe to use these friedelane triterpenoids for future biological applications as well as to explore more interesting and usefull multifunctionalized derivatives of the particular class of pentacyclic triterpenoids. vii Preface The thesis is the compilation of the research work carried out by the author under the supervision of Professor Pranab Ghosh in the Department of Chemistry, University of North Bengal during the period 2008 to 2015. It comprises a number of transformative reactions on different carbocyclic compounds. And as the author had privilege to work in the natural products laboratory, the carbocyclic compounds chosen as the starting substrates are some selective steroids and pentacyclic triterpenoids having immense practical utilizations. In short, a chemical compound or substance produced by a living organism —thus found in nature, is a natural product. Within the periphery of organic chemistry, we consider natural products, typically, as pure organic compounds (thus pure molecules) isolated from natural sources related to lives, directly or indirectly. Due to the widespread and increasingly demandable applications of these natural molecules, supply at a required amount has lead their preparation in the laboratory by the process of chemical synthesis, which indeed has enriched organic chemistry enormously by following a huge number of challenging targets. And considering the prime importance of steroids and pentacyclic triterpenoids in medicinal chemistry as well as in materials science, we have taken an opportunity to enrich this particular area of the natural products chemistry by synthesizing a number of interestingly useful molecules through different known/ new transformative protocols. I feel it an imperative, in my first opportunity, to express my heartfelt and sincere gratitude to my supervisor, Professor Pranab Ghosh, Department of Chemistry, University of North Bengal, West Bengal for providing me the opportunity to carry out my research work with all the marvellous supervision and utmost important suggestions. His continuous encouragement and guidance has played a pivotal role in furnishing a good basis for the present thesis. I would like to thank all the faculty members of the Department
Recommended publications
  • Critical Role of Oxidative Stress in Estrogen-Induced Carcinogenesis
    Critical role of oxidative stress in estrogen-induced carcinogenesis Hari K. Bhat*†, Gloria Calaf‡, Tom K. Hei*‡, Theresa Loya§, and Jaydutt V. Vadgama¶ *Department of Environmental Health Sciences, Mailman School of Public Health, 60 Haven Avenue-B1, Columbia University, New York, NY 10032; ‡Center for Radiological Research, Columbia University, New York, NY 10032; and Departments of §Pathology and ¶Medicine, Charles Drew University, Los Angeles, CA 90059 Communicated by Donald C. Malins, Pacific Northwest Research Institute, Seattle, WA, December 27, 2002 (received for review August 22, 2002) Mechanisms of estrogen-induced tumorigenesis in the target quinones generates oxidative stress and potentially harmful free organ are not well understood. It has been suggested that oxida- radicals that are postulated to be required for the carcinogenic tive stress resulting from metabolic activation of carcinogenic process, and analogous to the metabolic activation of hydrocar- estrogens plays a critical role in estrogen-induced carcinogenesis. bons and other nonsteroidal estrogen carcinogens (9, 19–22). We We tested this hypothesis by using an estrogen-induced hamster have investigated the role of oxidative stress in estrogen carci- renal tumor model, a well established animal model of hormonal nogenesis by using a well established hamster renal tumor model carcinogenesis. Hamsters were implanted with 17␤-estradiol (␤E2), that shares several characteristics with human breast and uterine 17␣-estradiol (␣E2), 17␣-ethinylestradiol (␣EE), menadione, a com- cancers, pointing to a common mechanistic origin (6, 9, 23). bination of ␣E2 and ␣EE, or a combination of ␣EE and menadione Different estrogens used in the present study differ in their for 7 months.
    [Show full text]
  • Pp375-430-Annex 1.Qxd
    ANNEX 1 CHEMICAL AND PHYSICAL DATA ON COMPOUNDS USED IN COMBINED ESTROGEN–PROGESTOGEN CONTRACEPTIVES AND HORMONAL MENOPAUSAL THERAPY Annex 1 describes the chemical and physical data, technical products, trends in produc- tion by region and uses of estrogens and progestogens in combined estrogen–progestogen contraceptives and hormonal menopausal therapy. Estrogens and progestogens are listed separately in alphabetical order. Trade names for these compounds alone and in combination are given in Annexes 2–4. Sales are listed according to the regions designated by WHO. These are: Africa: Algeria, Angola, Benin, Botswana, Burkina Faso, Burundi, Cameroon, Cape Verde, Central African Republic, Chad, Comoros, Congo, Côte d'Ivoire, Democratic Republic of the Congo, Equatorial Guinea, Eritrea, Ethiopia, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Kenya, Lesotho, Liberia, Madagascar, Malawi, Mali, Mauritania, Mauritius, Mozambique, Namibia, Niger, Nigeria, Rwanda, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, South Africa, Swaziland, Togo, Uganda, United Republic of Tanzania, Zambia and Zimbabwe America (North): Canada, Central America (Antigua and Barbuda, Bahamas, Barbados, Belize, Costa Rica, Cuba, Dominica, El Salvador, Grenada, Guatemala, Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, Puerto Rico, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Trinidad and Tobago), United States of America America (South): Argentina, Bolivia, Brazil, Chile, Colombia, Dominican Republic, Ecuador, Guyana, Paraguay,
    [Show full text]
  • Dalton Pharma Catalogue Steroids 12-19-12
    2012/2013 Version: December 31, 2012 Steroid Analytical Reference Standards and Drug Impurities Dalton Pharma Services: A Health Canada Approved Facility Level-8 Controlled Substances License on-site SCC Approved GLP Facility North American Manufactured and Shipped To Order Call: 1.800.567.5060 To Order Call: 416.661.2102 Email: [email protected] Email: [email protected] Page 2 Dalton Standards and Impurities Table of Contents Introduction/Company Profile 4 Custom Synthesis Overview 6 Contract Research/Medicinal Chemistry 7 Process Development Overview 8 Analytical Services 9 GMP API & Sterile Filling Services 11 Formulation Development Overview 12 Liposomes 13 Dalton Standards and Impurities 14 Establishment License 16 Certificate example 17 Steroids 18 Page 3 To Order Call: 1.800.567.5060 To Order Email: [email protected] Call: Company Profile About Dalton Pharma Services Dalton Pharma Services is a privately-held pharmaceutical services company that has been producing Fine Chemi- cals on a custom basis for research and chemical supply houses for over twenty-five years (Fluka, Aldrich, Sigma, Acros). We have identified and supplied many new re- agents for biological and pharmaceutical applications, this includes novel analogues and impurities of active pharma- ceuticals ingredients, as well as new linkers. We are lead- ers in process development, process improvement, and in the field of isolation of kilo quantities of biologically active molecules from natural sources. Dalton excels at advancing projects from R&D into GMP environments for its customers. With the ability to manufacture cGMP API's from bench scales to multi kilos we can meet most clinical and small scale commercial requirements.
    [Show full text]
  • United States Patent (19) 11 Patent Number: 6,068,830 Diamandis Et Al
    US00606883OA United States Patent (19) 11 Patent Number: 6,068,830 Diamandis et al. (45) Date of Patent: May 30, 2000 54) LOCALIZATION AND THERAPY OF FOREIGN PATENT DOCUMENTS NON-PROSTATIC ENDOCRINE CANCER 0217577 4/1987 European Pat. Off.. WITH AGENTS DIRECTED AGAINST 0453082 10/1991 European Pat. Off.. PROSTATE SPECIFIC ANTIGEN WO 92/O1936 2/1992 European Pat. Off.. WO 93/O1831 2/1993 European Pat. Off.. 75 Inventors: Eleftherios P. Diamandis, Toronto; Russell Redshaw, Nepean, both of OTHER PUBLICATIONS Canada Clinical BioChemistry vol. 27, No. 2, (Yu, He et al), pp. 73 Assignee: Nordion International Inc., Canada 75-79, dated Apr. 27, 1994. Database Biosis BioSciences Information Service, AN 21 Appl. No.: 08/569,206 94:393008 & Journal of Clinical Laboratory Analysis, vol. 8, No. 4, (Yu, He et al), pp. 251-253, dated 1994. 22 PCT Filed: Jul. 14, 1994 Bas. Appl. Histochem, Vol. 33, No. 1, (Papotti, M. et al), 86 PCT No.: PCT/CA94/00392 Pavia pp. 25–29 dated 1989. S371 Date: Apr. 11, 1996 Primary Examiner Yvonne Eyler S 102(e) Date: Apr. 11, 1996 Attorney, Agent, or Firm-Banner & Witcoff, Ltd. 87 PCT Pub. No.: WO95/02424 57 ABSTRACT It was discovered that prostate-specific antigen is produced PCT Pub. Date:Jan. 26, 1995 by non-proStatic endocrine cancers. It was further discov 30 Foreign Application Priority Data ered that non-prostatic endocrine cancers with Steroid recep tors can be stimulated with Steroids to cause them to produce Jul. 14, 1993 GB United Kingdom ................... 93.14623 PSA either initially or at increased levels.
    [Show full text]
  • WO 2018/060501 A2 05 April 2018 (05.04.2018) W ! P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/060501 A2 05 April 2018 (05.04.2018) W ! P O PCT (51) International Patent Classification: (71) Applicants: MYOVANT SCIENCES GMBH [CH/CH]; A61K 31/513 (2006.01) Viaduktstrasse 8, 405 1 Basel (CH). TAKEDA PHAR¬ MACEUTICAL COMPANY LIMITED [JP/JP]; 1-1, (21) International Application Number: Doshomachi 4-chome, Chuo-ku, Osaka-shi, Osaka, PCT/EP20 17/074907 541-0045 (JP). (22) International Filing Date: (72) Inventors: JOHNSON, Brendan Mark; 2017 Markham 29 September 2017 (29.09.2017) Drive, Chapel Hill, 275 14 (NC). SEELY, Lynn; 537 Occi (25) Filing Language: English dental Avenue, San Mateo, 94402 (US). MUDD, JR., Paul N.; 302 Beacon Falls Court, Cary, North Carolina 27519 (26) Publication Langi English (US). WOLLOWITZ, Susan; 32 Topper Court, Lafayette, (30) Priority Data: California 94549 (US). HIBBERD, Mark; The Old House, 62/402,034 30 September 2016 (30.09.2016) US Hawkley, Liss Hampshire GU33 6NQ (GB). TANIMO- 62/402,055 30 September 2016 (30.09.2016) US TO, Masataka; c/o Takeda Pharmaceutical Company Lim 62/402,150 30 September 2016 (30.09.2016) US ited, 1-1, Doshomachi 4-chome, Chuo-ku, Osaka-shi, O sa 62/492,839 0 1 May 2017 (01 .05.2017) US ka, 541-0045 (JP). RAJASEKHAR, Vijaykumar Reddy; 62/528,409 03 July 2017 (03.07.2017) US 20200 Quail Hollow Road, Apple Valley, California 92308 (54) Title: METHODS OF TREATING UTERINE FIBROIDS AND ENDOMETRIOSIS PBAC=0 Lumbar BMD CD n co CD P g CO O O CD Dose (mg) FIG.
    [Show full text]
  • WHO Drug Information Vol
    WHO Drug Information Vol. 29, No. 2, 2015 WHO Drug Information Contents Regulatory collaboration 153 Transparency WHO calls for disclosure of clinical trial 127 The African Vaccine Regulatory Forum results; Australia adopts new regulator (AVAREF): A platform for collaboration in a performance framework public health emergency 154 Databases Health Canada launches searchable inspection database; WHO launches WHO prequalification open access to its global medicines safety 133 Update on prequalification of diagnostics and database; EMA to record adverse events from medicines literature in EudraVigilance 155 Approved Cholic acid: for rare bile acid synthesis disorders; Eluxadoline : for irritable bowel disease; Empaglifozin & Norms and standards metformin : for diabetes; Evolocumab : to lower cholesterol; Isavuconazonium 138 Biotherapeutics and biosimilars sulfate: for certain invasive fungal infections; Atazanavir & cobicistat: for treatment of HIV-1 infection; Anthrax immunoglobulin (human); Dinutuximab : to prolong survival in children with high-risk neuroblastoma; Filgrastim-sndz :, first biosimilar in the U.S.; Tasimelteon : to regulate sleep patterns in blind adults; Safety news 157 Extensions of indications 142 Restrictions Moxifloxacin : for treatment of plague; Sirolimus : for very rare lung disease; Bromhexine : not to be used in children under six in New Zealand; Codeine for cough and cold : not to be used in children under 12; 158 Generic 142 Safety warnings Glatiramer acetate : Sitagliptin : thrombocytopenia; SGLT2 inhibitor diabetes
    [Show full text]
  • Relation to Hormonal Activity and Cell Proliferation1
    [CANCER RESEARCH 55, 4347-4351, October 1, 1995] Carcinogenic Activities of Various Steroidal and Nonsteroidal Estrogens in the Hamster Kidney: Relation to Hormonal Activity and Cell Proliferation1 Jonathan J. Li,2 Sara Antonia Li, Terry D. Oberley, and Jonathan A. Parsons Hormonal Carcinogenesis Laboratory, Division of Etiology and Prevention of Hormonal Cancers, University of Kansas Cancer Center, and Department of Pharmacology, Toxicology, and Therapeutics [J. J. L, S. A. L} and Preventive Medicine [J. J. L], University of Kansas Medical Center, Kansas City, Kansas 66160-7312; Pathology Service, William S. Middleton Memorial Veterans Administration Hospital, and Department of Pathology, University of Wisconsin Medical School. Madison, Wisconsin 53706 IT. D. O.J; and Department of Anatomy, University of Minnesota Medical School, Minneapolis, Minnesota 55417 ¡J.A. P.} ABSTRACT INTRODUCTION The therapeutic use of estrogens has been associated with an increased Numerous epidemiological studies have established causal relation risk of some of the most predominant, as well as less prevalent, cancers in ships between estrogen use and increased risk for some of the pre women. The estrogen-induced renal tumor is one of the primary animal dominant cancers in women, namely, breast and endometrium (1-3). models to evaluate the carcinogenic properties of estrogens. Correlations Ingestion of estrogens has also been associated with some less prev were made with various estrogens by using parameters of estrogenicity alent cancers at hepatic, cervico-vaginal, and ovarian sites (4-6). It is end points such as competitive binding, progesterone receptor induction, estimated that at least 20 million women in the United States take and alterations in prolactin levels; in vitro renal proximal cell prolifera estrogenic hormones, largely but not solely for contraception, for the tion; and in vivo estrogen-induced carcinogenicity.
    [Show full text]
  • Relationship Between the Results of in Vitro Receptor Binding Assay To
    Available online at www.sciencedirect.com Toxicology in Vitro 22 (2008) 225–231 www.elsevier.com/locate/toxinvit Relationship between the results of in vitro receptor binding assay to human estrogen receptor a and in vivo uterotrophic assay: Comparative study with 65 selected chemicals Yumi Akahori a,b,*, Makoto Nakai b, Kanji Yamasaki c, Mineo Takatsuki b, Yasuyuki Shimohigashi d, Masahiro Ohtaki a a Department of Human Environmental Science, Ochanomizu University, 2-1-1, Otsuka, Bunkyo-ku, Tokyo 112-8610, Japan b Chemicals Assessment Center, Chemicals Evaluation and Research Institute, Japan (CERI) 1600, Shimo-Takano, Sugito-machi, Kitakatsushika-gun, Saimata 345-0043, Japan c Chemicals Assessment Center, Chemicals Evaluation and Research Institute, Japan (CERI) 3-822 Ishii-machi, Hita, Oita 877-0061, Japan d Department of Chemistry, Faculty and Graduate School of Sciences, Kyushu University, 6-10-1 Hakozaki, Higashi-ku, Fukuoka 812-8581, Japan Received 2 May 2007; accepted 8 August 2007 Available online 23 August 2007 Abstract For screening chemicals possessing endocrine disrupting potencies, the uterotrophic assay has been placed in a higher level in the OECD testing framework than the ER binding assay to detect ER-mediated activities. However, there are no studies that can demon- strate a clear relationship between these assays. In order to clarify the relationship between the in vitro ER binding and in vivo utero- trophic assays and to determine meaningful binding potency from the ER binding assay, we compared the results from these assays for 65 chemicals spanning a variety of chemicals classes. Under the quantitative comparison between logRBAs (relative binding affinities) and logLEDs (lowest effective doses), the log RBA was well correlated with both logLEDs of estrogenic and anti-estrogenic compounds at r2 = 0.67 (n = 28) and 0.79 (n = 23), respectively.
    [Show full text]
  • EVALUATION of DIETARY PHYTOCHEMICALS on SEX DIFFERENTIATION and GROWTH in NILE TILAPIA (Oreochromis Niloticus)
    EVALUATION OF DIETARY PHYTOCHEMICALS ON SEX DIFFERENTIATION AND GROWTH IN NILE TILAPIA (Oreochromis niloticus) DISSERTATION Presented in Partial Fulfillment of the Requirement for the Degree of Doctor of Philosophy in the Graduate School of The Ohio State University By Gustavo Alejandro Rodriguez Montes de Oca, M.S. * * * * * The Ohio State University 2005 Dissertation Committee: Approved by Konrad Dabrowski, Adviser. John L. Heywood Joseph S. Ottobre _____________________ Roman P. Lanno Adviser Graduate Program in Natural Resources ABSTRACT Monosex fish stocks are desirable in aquaculture in order to control reproduction and select the gender that displays faster growth characteristics in a particular species. Synthetic steroids are commonly used to sex-reverse tilapia but because of their potential hazards; the use of new chemicals is a potential alternative to be explored. Phytochemicals present in many plants have many reported biological properties. This study explores the possible utilization of selected phytochemicals as potential in vivo enzymatic inhibitors of aromatase and of nuclear estrogen receptors antagonist in gonad germ cells. Such response could modulate the sex differentiation process of the gonad in sexually undifferentiated Nile tilapia. In a first trial, experimental diets were supplemented with genistein (500 mg/kg) and quercetin (10 g/kg) along with the androgenic synthetic hormone 17α-methyltestosterone (MT) (60 mg/kg) and we evaluated the in vivo response to the dietary administration of these phytochemicals towards the masculinization of first feeding genetically all-female Nile tilapia (Oreochromis niloticus). In a second trail, experimental diets with caffeic acid (500 mg/kg), chrysin (500 mg/kg), daidzein (500 mg/kg) including MT (60 mg/kg), along with the steroidal aromatase inhibitor 1,4,6-androstatrien-3-17-dione (ATD) (150 mg/kg), and a ii second steroidal compound spironolactone (500 mg/kg), were administered to first feeding tilapia in order to assess the response in final phenotypic sex of the gonad in experimental fish.
    [Show full text]
  • OECD Environment, Health and Safety Publications
    OECD Environment, Health and Safety Publications Series on Testing and Assessment No. XX DRAFT DETAILED REVIEW PAPER ON ENVIRONMENTAL ENDOCRINE DISRUPTOR SCREENING: THE USE OF RECEPTOR BINDING AND TRANSACTIVATION ASSAYS IN FISH Environment Directorate ORGANISATION FOR ECONOMIC CO-OPERATION AND DEVELOPMENT Paris 16 April, 2009 1 Also published in the Series on Testing and Assessment: No. 1, Guidance Document for the Development of OECD Guidelines for Testing of Chemicals (1993; reformatted 1995, revised 2006) No. 2, Detailed Review Paper on Biodegradability Testing (1995) No. 3, Guidance Document for Aquatic Effects Assessment (1995) No. 4, Report of the OECD Workshop on Environmental Hazard/Risk Assessment (1995) No. 5, Report of the SETAC/OECD Workshop on Avian Toxicity Testing (1996) No. 6, Report of the Final Ring-test of the Daphnia magna Reproduction Test (1997) No. 7, Guidance Document on Direct Phototransformation of Chemicals in Water (1997) No. 8, Report of the OECD Workshop on Sharing Information about New Industrial Chemicals Assessment (1997) No. 9, Guidance Document for the Conduct of Studies of Occupational Exposure to Pesticides during Agricultural Application (1997) No. 10, Report of the OECD Workshop on Statistical Analysis of Aquatic Toxicity Data (1998) No. 11, Detailed Review Paper on Aquatic Testing Methods for Pesticides and industrial Chemicals (1998) No. 12, Detailed Review Document on Classification Systems for Germ Cell Mutagenicity in OECD Member Countries (1998) No. 13, Detailed Review Document on Classification Systems for Sensitising Substances in OECD Member Countries 1998) No. 14, Detailed Review Document on Classification Systems for Eye Irritation/Corrosion in OECD Member 2 Countries (1998) No.
    [Show full text]
  • Carcinogenic Activities of Various Steroidal and Nonsteroidal Estrogens in the Hamster Kidney: Relation to Hormonal Activity and Cell Proliferation1
    [CANCER RESEARCH 55, 4347-4351, October 1, 1995] Carcinogenic Activities of Various Steroidal and Nonsteroidal Estrogens in the Hamster Kidney: Relation to Hormonal Activity and Cell Proliferation1 Jonathan J. Li,2 Sara Antonia Li, Terry D. Oberley, and Jonathan A. Parsons Hormonal Carcinogenesis Laboratory, Division of Etiology and Prevention of Hormonal Cancers, University of Kansas Cancer Center, and Department of Pharmacology, Toxicology, and Therapeutics [J. J. L, S. A. L} and Preventive Medicine [J. J. L], University of Kansas Medical Center, Kansas City, Kansas 66160-7312; Pathology Service, William S. Middleton Memorial Veterans Administration Hospital, and Department of Pathology, University of Wisconsin Medical School. Madison, Wisconsin 53706 IT. D. O.J; and Department of Anatomy, University of Minnesota Medical School, Minneapolis, Minnesota 55417 ¡J.A. P.} ABSTRACT INTRODUCTION The therapeutic use of estrogens has been associated with an increased Numerous epidemiological studies have established causal relation risk of some of the most predominant, as well as less prevalent, cancers in ships between estrogen use and increased risk for some of the pre women. The estrogen-induced renal tumor is one of the primary animal dominant cancers in women, namely, breast and endometrium (1-3). models to evaluate the carcinogenic properties of estrogens. Correlations Ingestion of estrogens has also been associated with some less prev were made with various estrogens by using parameters of estrogenicity alent cancers at hepatic, cervico-vaginal, and ovarian sites (4-6). It is end points such as competitive binding, progesterone receptor induction, estimated that at least 20 million women in the United States take and alterations in prolactin levels; in vitro renal proximal cell prolifera estrogenic hormones, largely but not solely for contraception, for the tion; and in vivo estrogen-induced carcinogenicity.
    [Show full text]
  • United States Patent [11] 3,626,061 72) Inventors John C
    United States Patent [11] 3,626,061 72) Inventors John C. Babcock; CLAM: This invention relates to novel 7 a-methyl-17a-alky J. Allan Campbell, both of Kalamazoo, lated estradiols and processes for their preparation; more par Mich. 21 Appl. No. 666,466 ticularly to those compounds embraced by the formula (11) (22 Filed Sept. 8, 1967 CH 45) Patented Dec. 7, 1971 OR 73) Assignee The Upjohn Company Kalamazoo, Mich. Continuation-in-part of application Ser. No. 114,621, June 5, 1961, now Patent No. r 3,341,557, Continuation-in-part of N/ application Ser. No. 69,557, Nov. 6, 1960, now abandoned. This application Sept. 8, RO --CH3 1967, Ser. No. 666,466 wherein R is selected from the group consisting of hydrogen, the acyl radical of a hydrocarbon carboxylic acid containing from one through 12 carbon atoms, an alkyl radical containing from one through 8 carbon atoms, tetrahydrofuranyl, tetrahydropyranyl, 5-substituted tetrahydropyranyl, and a silyl radical of the formula (54) COMPOSITIONS COMPRISING 7a-METHYL-17 ALKYLATED ESTRADIOLS 6 Claims, No Drawings RNs, (52) U.S. Ct........................................................ 424/238, R 260/397.5, 260/239.55, 260/397.4, 19515 (5ll int. Cli....................................................... C07c69/08 wherein R, R and Ra are selected from the group con (50 Field of Search............................................ 260/.397.5 sisting of alkyl of one through eight carbon atoms and phenyl, R' is selected from the group consisting of hydrogen, (56) References Cited methyl, ethyl and 1-propynyl, and R' is selected from the UNITED STATES PATENTS group consisting of hydrogen, the acyl radical of a hydro 3,318,929 5/967 Anner et al..................
    [Show full text]